Factors Associated With Initiation of Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonists in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the Kidney CHAMP Trial

What is it about?

Why did we undertake this study? The influence of social determinants of health (SDOH) on prescribing sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1RA) prescribing are not well known among persons with type 2 diabetes and chronic kidney disease (CKD). What is the specific question(s) we wanted to answer? What individual- and contextual-level SDOH factors are associated with SGLT2i/GLP1RA initiation? Can a CKD population health management (PHM) intervention modify the effect of these factors on SGLT2i/GLP1RA initiation? What did we find? SGLT2i/GLP1RA initiation decreased with higher age and increased with HbA1c. SDOH factors were not associated with initiation of these drugs. The PHM intervention did not affect these associations. What are the implications of our findings? Our findings suggest targets for new interventions to increase incident use of SGLT2i/GLP1RA among CKD patients with type 2 diabetes.

Featured Image